

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Sisram Medical Ltd

(Incorporated in Israel with limited liability)

(Stock Code: 1696)

RESIGNATION OF DIRECTORS APPOINTMENT OF DIRECTORS CHANGE OF CHIEF OPERATING OFFICER AND APPOINTMENT OF CHIEF STRATEGY OFFICER

Resignation of Non-Executive Directors

The board of directors (the “**Board**”) of Sisram Medical Ltd (the “**Company**”) hereby announced that Mr. Chun LI and Ms. Yu HU have tendered their resignation from the positions of non-executive directors of the Company with effect from 19 March 2018 due to their other work commitments.

Each of Mr. Chun LI and Ms. Yu HU has confirmed that he/she has no disagreement with the Board and there are no matters relating to his/her resignation that need to be brought to the attention of the shareholders of the Company (the “**Shareholders**”).

Appointment of Directors

The Board also announced that, with effect from 19 March 2018, Mr. Jianping HUA (“**Mr. Hua**”) has been appointed as an executive director of the Company and Ms. Yang YANG (“**Ms. Yang**”) has been appointed as a non-executive director of the Company.

Mr. Hua, aged 36, has been the Chief Financial Officer and Secretary to the board of directors of the Company since February 2014. He is responsible for the financial operation, board administrative matters and financing and investment activities of the Group. Mr. Hua has more than 10 years professional financial and investment experience. He held a number of positions comprising vice director of financial audit, director of financial audit and deputy general manager of the finance department of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (“**Fosun Pharma**”) since February 2011 and is currently the vice chief financial officer of Fosun Pharma and the vice

president of Medical Technology Division of Fosun Pharma. Prior to joining Fosun Pharma, Mr. Hua worked as an audit manager in PricewaterhouseCoopers from August 2005 to February 2011. Mr. Hua obtained a bachelor's degree in English from Shanghai University (上海大學) in the PRC in July 2005.

Ms. Yang, aged 40, has been the senior manager of Sincere Holding Group Co., Ltd. (協信控股集團) in charge of matters relating to employees' performance and development and the human resources manager of Sino-Singapore Interconnection Investment Fund Management Co., Ltd. (中新互聯互通投資基金管理有限公司) since March 2016. Previously, she worked as the human resources manager from February 2014 to January 2016 and the assistant to the chairman of the board of directors from January 2015 to April 2015, respectively, of Zhongtai Hengyuan Industrial Co., Ltd. (中太恒源實業有限公司), a partner of Peking University Management Consulting Co., Ltd. (北大縱橫管理諮詢有限公司) responsible for human resources related consultation from December 2008 to November 2013, and a purchasing representative for supply chain management of Shanghai Siemens Mobile Communications Company (上海西門子移動通訊公司) from September 2004 to September 2008. Ms. Yang obtained a bachelor's degree in Computer Science and Technology from Harbin Institute of Technology (哈爾濱工業大學) in the PRC in July 2000, a master's degree in Electronic Commerce from the University of Wyoming in the United States in August 2004 and a doctor's degree in Corporate Management from the Swiss Federal Institute of Technology Zurich in September 2008.

Except as disclosed above, each of Mr. Hua and Ms. Yang did not hold any directorship in listed public companies in the three years preceding the date of this announcement, nor does any of them has any relationship with any other director or senior management of the Company, or substantial or controlling shareholders of the Company.

As at the date of this announcement, each of Mr. Hua and Ms. Yang does not have any interest in the shares or underlying shares of the Company and its associated corporations within the meaning of Part XV of the Securities and Futures Ordinance.

Mr. Hua has entered into a letter of appointment with the Company for a period commencing from 19 March 2018 and ending on 30 August 2020 in accordance with the Articles of Association of the Company. Ms. Yang has entered into a letter of appointment with the Company for a period commencing from 19 March 2018 and ending on 30 August 2020 in accordance with the Articles of Association of the

Company. Pursuant to the articles of association of the Company, both Mr. Hua and Ms. Yang will hold offices as executive director and non-executive director, respectively, of the Company until the forthcoming annual general meeting of the Company and will then stand for re-election at that meeting. Neither Mr. Hua nor Ms. Yang will receive any emolument from the Company for acting as directors of the Company.

Save as disclosed above, there is no other matter that needs to be brought to the attention of the Shareholders in connection with Mr. Hua and Ms. Yang's appointments and there is no other information that should be disclosed pursuant to Rule 13.51(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

The Board would like to extend their warm welcome to Mr. Hua and Ms. Yang in joining the Board.

Change of Chief Operating Officer

The Board also announced that Mr. Ronen LAZAROVICH (“**Mr. Lazarovich**”) has tendered his resignation from the position of Chief Operating Officer of the Company with effect from 31 March 2018 due to his other work commitments. Mr. Lazarovich has confirmed that he has no disagreement with the Board and there are no matters relating to his resignation that need to be brought to the Shareholders.

The Board also announced that Mr. Ran EZIONI (“**Mr. Ezioni**”) will assume the position of Chief Operating Officer of the Company with effect from 1 April 2018.

Mr. Ezioni brings over 22 years of multi-dimensional experience in the fields of global operations, supply chain management, information technology, outsourcing and service and maintenance in various industries, including the medical aesthetic industry. Prior to joining the Company, Mr. Ezioni served as a vice president of global supply chain, purchasing and information technology at Arkal Automotive, a global developer and worldwide manufacturer of solutions for the global automotive industry.

Mr. Ezioni holds a bachelor of science degree in Industrial Engineering from the Technion, the Israeli Institute of Technology, with honors, and is Certified Six Sigma Black Belt (CSSBB) by the American Society for Quality.

Appointment of Chief Strategy Officer

The Board also announced the appointment of Mr. Avraham FARBSTEIN (“**Mr. Farbstein**”) as Chief Strategy Officer of the Company with effect from 19 March 2018.

Mr. Farbstein has been serving as chief executive officer of the Group’s North America operations since March 2013, successfully leading major business development and business expansion ventures in this strategic market.

Mr. Farbstein has more than 35 years of experience in the medical and aesthetic devices industry beginning with his involvement in research and development of one of the first lasers introduced into the surgical devices field.

Mr. Farbstein holds a bachelor of science degree in electric engineering from Tel Aviv University in Israel.

By Order of the Board
Sisram Medical Ltd
Yi LIU
Chairman

Hong Kong, 19 March 2018

As at the date of this announcement, the Board comprises Mr. Yi LIU, Mr. Lior Moshe DAYAN and Mr. Jianping HUA as executive directors; Mr. Yifang WU, Mr. Yao WANG and Ms. Yang YANG as non-executive directors; Mr. Heung Sang Addy FONG, Mr. Chi Fung Leo CHAN, Ms. Jenny CHEN and Mr. Kai Yu Kenneth LIU as independent non-executive directors.